A randomized, double-blind, parallel group, 52-week study evaluating the efficacy, safety and tolerability of NVA237 in patients with poorly controlled asthma
Status: Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 16 Feb 2018
Price : $35 *
At a glance
- Drugs Glycopyrrolate (Primary)
- Indications Asthma
- Focus Registrational; Therapeutic Use
- Sponsors Novartis; Novartis Pharma A.G.
- 30 Oct 2014 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 06 Oct 2014 Planned End Date changed from 1 Dec 2016 to 1 May 2017 as reported by ClinicalTrials.gov record.
- 06 Oct 2014 Planned primary completion date changed from 1 Dec 2016 to 1 May 2017 as reported by ClinicalTrials.gov record.